BioSpace News Archive

Catalyst Pharmaceuticals, Inc. (Catalyst) (Nasdaq: CPRX), today reported that it has received a positive decision from the 11th Circuit Court of Appeals in its appeal to overturn a District Court decision upholding the U.S. Food and Drug Administration’s (FDA) approval of another amifampridine product, Ruzurgi®

Rapid Micro Biosystems, Inc. (Nasdaq: RPID) (“Rapid Micro”), is excited to announce its participation as an exhibitor and presenter of two scientific posters at the 2021 Parenteral Drug Association (PDA) Pharmaceutical Microbiology Conference.

Today, the U.S. Food and Drug Administration cleared the first new major technological improvement for Computed Tomography (CT) imaging in nearly a decade.

AiM Medical Robotics, a leading developer of MRI-safe intraoperative robotics for neurosurgery, today announced that it is hosting a panel discussion and presenting at BioFuture

The American Diabetes Association® announced that applications for grants are being accepted for two new research initiatives, leveraging nutrition and lifestyle for diabetes prevention, and precision medicine to improve the management of diabetes.

The International Society for Heart and Lung Transplantation Academies have returned. The ISHLT Academies are standalone educational courses designed to improve and maintain the highest possible standards in the care of patients with advanced heart and lung disease.

AB Science SA reports its revenues for the first half of 2021 and provides an update on its activities.

Iridex Corporation, a provider of innovative ophthalmic laser-based medical products for the treatment of glaucoma and retinal diseases, announced the Company plans to participate in the upcoming Lytham Partners Fall 2021 Investor Conference.

Ascendis Pharma A/S (Nasdaq: ASND), a biopharmaceutical company using its innovative TransCon technologies to potentially create new treatments to make a meaningful difference in patients’ lives, today announced presentations featuring new data about its investigational TransCon PTH product candidate at the American Society for Bone & Mineral Research (ASBMR) 2021 Annual Meeting.

AnPac Bio-Medical Science Co., Ltd., a biotechnology company with operations in the United States and China, announced that it has received a written notification from the Nasdaq Stock Market LLC dated September 24, 2021 indicating that the Company is not in compliance with the minimum Market Value of Listed Securities set forth in the Nasdaq Rules for continued listing on the Nasdaq Global Market.